Anthropic has established a wet lab in the San Francisco Bay Area, specifically for physical biology research. This lab incorporates AI systems, such as Claude, into the experimental process, with life sciences being a primary focus of investment. At present, the lab's use is not confined to drug discovery, nor does it undertake clinical trials. Rather, it addresses needs that have been persistently neglected by the industry, thereby steering clear of direct rivalry with pharmaceutical firms. The company is delving into the physical automation capabilities of AI-guided robots, all the while maintaining a delicate balance between expediting R&D and managing risks. Previously, Anthropic recognized the potential hazards associated with its systems being exploited for bioweapon development. This realization prompted the CEO to advocate for a deceleration in AI development. Furthermore, Anthropic has introduced Claude Science, appointed the CEO of Novartis to its board of directors, and acquired Coefficient Bio. The company is bolstering its investment in the lab and actively seeking out relevant talent, with the ambitious goal of propelling progress in life sciences by an order of magnitude. The company is channeling its efforts into technical avenues such as bispecific and trispecific antibodies, which hold promise for advancing research on diseases previously deemed "undruggable." Currently, Anthropic has forged collaborations with numerous pharmaceutical companies and ensures the segregation of customer data for processing.